{"schema_version":"secwatch.filing_event.v1","accession":"0001367644-25-000019","form_type":"8-K","ticker":"EBS","cik":"0001367644","company_name":"Emergent BioSolutions Inc.","filed_at":"2025-03-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.442669+00:00","generated_at":"2026-05-25T17:07:14.740912+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Emergent BioSolutions Q4 loss narrows 37% to $31.3M; FY24 revenue $1.04B; guides FY25 EBITDA $150-200M","bullets":["Q4 2024 total revenue $194.7M, down 30% YoY; net loss $31.3M vs. $49.5M loss in Q4 2023.","FY 2024 total revenue $1.04B (flat YoY); net loss $190.6M vs. $760.5M loss; adjusted EBITDA $183.1M vs. ($22.3M) loss.","FY 2025 guidance: revenue $750-850M; adjusted EBITDA $150-200M; segment adjusted gross margin 48-51%.","NARCAN sales fell 41% in Q4; Smallpox MCM sales surged 565% on ACAM2000 exports; Anthrax MCM down 71%.","Appointed CEO Joseph Papa; received ~$550M medical countermeasure awards; FDA approved ACAM2000 for mpox prevention."],"urls":{"canonical":"https://secwatch.observer/filing/0001367644-25-000019","json":"https://secwatch.observer/filing/0001367644-25-000019.json","markdown":"https://secwatch.observer/filing/0001367644-25-000019.md","text":"https://secwatch.observer/filing/0001367644-25-000019.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1367644/000136764425000019/0001367644-25-000019-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1367644/000136764425000019/ebs-20250303.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T17:07:14.740912+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}